A Phase 1, Comparator-Controlled, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Number and percentage of participants experiencing any influenza like illnesses (ILI)
研究概览
简要总结
This is a Phase 1, single-site, comparator-controlled, dosage-escalating study of an intramuscularly administered mRNA-LNP vaccine encoding for DCVC H1 HA in up to 50 adult volunteers aged 18 to 49 years, inclusive. This study is designed to assess the safety and immunogenicity of two doses of DCVC H1 HA mRNA vaccine administered 28 days apart. Eligible participants will be sequentially enrolled into dosage escalation groups (10 mcg, 25 mcg, and 50 mcg). A separate group of 10 participants will receive one dose of the licensed quadrivalent influenza vaccine (IIV4). Enrollment of participants into the IIV4 group is limited to when the vaccine is available for a given year. Concurrent enrollment of the IIV4 group and any pre-specified study product group or groups may present logistical challenges due to the availability of the IIV4 vaccine and may preclude enrollment of all study participants prior to the subsequent off-season. Participants receiving IIV4 will be followed for safety but only their immune responses will be compared to those of participants receiving DCVC H1 HA mRNA vaccine. Dosing of DCVC H1 HA mRNA vaccine will commence at the lowest dose (10 mcg) and only escalate to the next highest dose if safety concerns are not identified.
For each DCVC H1 HA mRNA vaccine dosing group, the first two participants enrolled will be considered the sentinel subgroup. After the two participants in the Low Dose sentinel subgroup are enrolled and given their first vaccination, enrollment and subsequent vaccinations in that dosing group will then be stopped until Day 3. This review will be conducted by a Safety Review Committee (SRC). If no halting criteria are met, the SRC will allow administration of the second dose for the sentinel subgroup and continued enrollment of the remaining 8 Low Dose Group participants (expanded subgroup) to complete enrollment of 10 participants. In order for a timely receipt of a second dose of study product on Day 29, SRC review and approval must occur prior to Study Day 28 for the first sentinel participant in the Low Dose Group. After the Low Dose Group enrollment is completed and both doses have been administered, enrollment will be stopped pending SRC review. After all participants in the Low Dose Group have completed the Day 36 visit, the SRC will review the clinical laboratory, reactogenicity, and adverse event information through the Day 36 visit for all Low Dose Group participants that received two doses. Approval by the SRC will allow dose escalation and initiation of enrollment of the Medium Dose Group sentinel subgroup. The Medium and High Dose sentinel and expanded groups will be enrolled as described above for the Low Dose sentinel and expanded groups, respectively, with the High Dose expanded subgroup enrolling up to 18 individuals.
The primary objective of this study is to assess the safety of two doses of DCVC H1 HA mRNA Vaccine administered intramuscularly in healthy adults (18-49 yrs) at dosage levels of 10 mcg, 25 mcg, and 50 mcg.
详细描述
This is a Phase 1, single-site, comparator-controlled, dosage-escalating study of an intramuscularly administered mRNA-LNP vaccine encoding for DCVC H1 HA in up to 50 adult volunteers aged 18 to 49 years, inclusive. This study is designed to assess the safety and immunogenicity of two doses of DCVC H1 HA mRNA vaccine administered 28 days apart. Eligible participants will be sequentially enrolled into dosage escalation groups (10 mcg, 25 mcg, and 50 mcg). A separate group of 10 participants will receive one dose of the licensed quadrivalent influenza vaccine (IIV4). Enrollment of participants into the IIV4 group is limited to when the vaccine is available for a given year. Concurrent enrollment of the IIV4 group and any pre-specified study product group or groups may present logistical challenges due to the availability of the IIV4 vaccine and may preclude enrollment of all study participants prior to the subsequent off-season. Participants receiving IIV4 will be followed for safety but only their immune responses will be compared to those of participants receiving DCVC H1 HA mRNA vaccine. Dosing of DCVC H1 HA mRNA vaccine will commence at the lowest dose (10 mcg) and only escalate to the next highest dose if safety concerns are not identified.
For each DCVC H1 HA mRNA vaccine dosing group, the first two participants enrolled will be considered the sentinel subgroup. After the two participants in the Low Dose sentinel subgroup are enrolled and given their first vaccination, enrollment and subsequent vaccinations in that dosing group will then be stopped until Day 3. This review will be conducted by a Safety Review Committee (SRC). If no halting criteria are met, the SRC will allow administration of the second dose for the sentinel subgroup and continued enrollment of the remaining 8 Low Dose Group participants (expanded subgroup) to complete enrollment of 10 participants. In order for a timely receipt of a second dose of study product on Day 29, SRC review and approval must occur prior to Study Day 28 for the first sentinel participant in the Low Dose Group. After the Low Dose Group enrollment is completed and both doses have been administered, enrollment will be stopped pending SRC review. After all participants in the Low Dose Group have completed the Day 36 visit, the SRC will review the clinical laboratory, reactogenicity, and adverse event information through the Day 36 visit for all Low Dose Group participants that received two doses. Approval by the SRC will allow dose escalation and initiation of enrollment of the Medium Dose Group sentinel subgroup. The Medium and High Dose sentinel and expanded groups will be enrolled as described above for the Low Dose sentinel and expanded groups, respectively, with the High Dose expanded subgroup enrolling up to 18 individuals.
The primary objective of this study is to assess the safety of two doses of DCVC H1 HA mRNA Vaccine administered intramuscularly in healthy adults (18-49 yrs) at dosage levels of 10 mcg, 25 mcg, and 50 mcg. The secondary objective of this study is to assess the serum antibody responses to two doses of DCVC H1 HA mRNA Vaccine administered intramuscularly 28 days apart in healthy adults at dosage levels of 10 mcg, 25 mcg, and 50 mcg in comparison to a standard dose of IIV4.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provide written informed consent prior to initiation of any study procedure.
- •Are able to understand and comply with planned study procedures and be available for all study visits.
- •Are males or non-pregnant, non-breastfeeding females, 18 to 49 years of age, inclusive at time of enrollment.
- •Must agree to collection of venous blood and nasal absorption specimens per protocol and enrollment in DMID 19-0025 biorepository protocol for use of residual blood specimens.
- •Are in good health* and not have clinically significant medical, psychiatric, chronic or intermittent health conditions including those listed in
排除标准
- •(Section 5.3) *Refer to the protocol specific Manual of Procedures (Section 4.3) for this definition.
- •Does not have an ongoing symptomatic condition* for which participant has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan.
- •*e.g., ongoing fatigue without a diagnosis for symptom.
- •Pulse is 50 to 100 beats per minute, inclusive.
- •Systolic blood pressure is 90 to 139 mmHg, inclusive.
- •Diastolic blood pressure is 55 to 89 mmHg, inclusive.
- •Body mass index (BMI) of 18 kilograms/square meter (kg/m^2) to <35 kg/m^2 (inclusive) and weight >/=110 lbs. at screening.
- •Women of childbearing potential* must agree to use or have practiced true abstinence or use at least 1 acceptable primary form of contraception. **
- •Not of child bearing potential - post-menopausal females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, salpingectomy, or Essure placement with history of documented radiological confirmation test at least 90 days after the procedure)
- •True abstinence is 100% of time no sexual intercourse (male's penis enters the female's vagina). (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).
- •Acceptable forms of primary contraception include monogamous relationship with a vasectomized partner who has been vasectomized for 180 days or more prior to the participant receiving the study product, tubal ligation, intrauterine devices, birth control pills, and injectable/implantable/insertable hormonal birth control products.
- •Must use at least one acceptable primary form of contraception or true abstinence for at least 30 days prior to receipt of study product and at least one acceptable primary form of contraception or true abstinence for at least 30 days following receipt of study product.
- •Women of childbearing potential* must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to each study vaccination.
- •Male participants receiving DCVC H1 HA mRNA Vaccine must agree to refrain from donating sperm and to use contraception until day 90 after last vaccination. **
- •Acceptable contraception includes abstinence from intercourse with a female of childbearing potential or use of a male condom when engaging in any activity that allows for passage of ejaculate to a female during the intervention period for at least 90 days after last study vaccination.
- •Males in the immunogenicity comparator group do not have to refrain from sperm donation or abstain from intercourse or agree to use a male condom for purposes of this study.
- •Exclusion Criteria:
- •Have an acute illness* or fever (body temperature >/= 38.0°C/100.4°F), as determined by the site PI or appropriate sub-investigator, within 72 hours prior to study vaccination.
- •*An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the site PI or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol.
- •Have any medical disease or condition that, in the opinion of the site PI or appropriate sub-investigator, is a contraindication to study participation. **
- •* Including acute, subacute, intermittent or chronic medical disease or condition that would place the participant at an unacceptable risk of injury, render the participant unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the participant's successful completion of this trial.
- •Has a screening laboratory* > Grade
- •*White blood cell count, absolute neutrophil count, absolute lymphocyte count, hemoglobin, platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, creatinine, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, lipase
- •Has a positive urine toxicology screen (i.e., non-prescribed amphetamines, cocaine, and opiates).
- •ECG is deemed to be clinically significant* by the PI or appropriate sub-investigator.
- •*ECG consistent with probable or possible myocarditis/pericarditis or demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results. An ECG that shows an average QTcF (Fridericia's correction) interval >450 msec, complete left bundle branch block, signs of an acute or indeterminate-age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias.
- •Troponin (Troponin T, High Sensitivity) outside the laboratory normal range at screening.
- •Have any known or suspected immunosuppressive condition, acquired or congenital, or autoimmune conditions as determined by history and/or physical examination.
- •Have immunosuppression resulting from any treatment including a recent history (within 6 months prior to administration of study vaccine) or use of immunosuppressive or immune-modifying drugs.
- •Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior to study vaccination.
- •Have known active or recently active (12 months) neoplastic disease or a history of any hematologic malignancy. Non-melanoma, treated, skin cancers are permitted.
- •Have known human immunodeficiency virus, hepatitis B or hepatitis C infection at screening.
- •Have a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at screening.
- •Have known chronic liver disease, including fatty liver disease.
- •Have known hypersensitivity or allergy to any components of the study vaccine (including polyethylene glycol or egg protein).
- •Have a history of a severe reaction including allergic reaction following previous immunization with an investigational, authorized, or approved influenza vaccine or mRNA containing vaccine.
- •Have a history of Guillain-Barré Syndrome.
- •Have a known history of myocarditis, pericarditis, or myopericarditis.
- •Have a history of alcohol or drug abuse within 3 years prior to study vaccination.
- •Have any diagnosis, current or past, of schizophrenia, bipolar disease or other psychiatric diagnosis that may interfere* with participant compliance or safety evaluations.
- •* As determined by the site PI or appropriate sub-investigator.
- •Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others within 5 years prior to study vaccination.
- •Have taken oral or parenteral (including intra-articular) corticosteroids of any dose within 30 days prior to study vaccination. Intranasal or topical (skin or eyes) corticosteroids are permitted.
- •Have taken high-dose inhaled or nebulized corticosteroids* within 30 days prior to study vaccination.
- •* High-dose defined as per age as using inhaled high-dose per reference chart in the National Heart, Lung and Blood Institute Guidelines for the Diagnosis and Management of Asthma (EPR-3) or other lists published in UPTODATE
- •Have any significant disorder of coagulation requiring ongoing or intermittent treatment.
- •Have received any approved or authorized vaccines other than seasonal influenza vaccine within 60 days before enrollment.
- •Have received seasonal influenza vaccine within the 90 days prior to enrollment.
- •Have a known history of documented influenza infection with the past 90 days.
- •Have a history of receipt of an investigational H1 influenza vaccine within the past 10 years.
- 另有 9 项未显示
研究组 & 干预措施
Arm 1
Healthy adults, 18 to 49 years of age will receive 10 mcg of DCVC H1 HA mRNA Vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A dose escalation safety evaluation will occur to ensure the safety data support proceeding to the higher dose group. N = 10
干预措施: Sodium Chloride, 0.9% (Other)
Arm 2
Healthy adults, 18 to 49 years of age will receive 25 mcg of DCVC H1 HA mRNA vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A dose escalation safety evaluation will occur to ensure the safety data support proceeding to the higher dose group. N = 10
干预措施: DCVC H1 HA mRNA vaccine (Biological)
Arm 2
Healthy adults, 18 to 49 years of age will receive 25 mcg of DCVC H1 HA mRNA vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A dose escalation safety evaluation will occur to ensure the safety data support proceeding to the higher dose group. N = 10
干预措施: Sodium Chloride, 0.9% (Other)
Arm 3
Healthy adults, 18 to 49 years of age will receive 50 mcg of DCVC H1 HA mRNA vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A safety evaluation will occur to ensure the safety data support proceeding to the optimal dose group. N = 20
干预措施: DCVC H1 HA mRNA vaccine (Biological)
Arm 4
Healthy adults, 18 to 49 years of age will receive 60 mcg of Licensed quadrivalent inactivated influenza vaccine (IIV4), Fluzone Quadrivalent, administered intramuscularly to the upper arm/deltoid once. N = 10
干预措施: Quadrivalent Recombinant Seasonal Influenza Vaccine (Biological)
Arm 3
Healthy adults, 18 to 49 years of age will receive 50 mcg of DCVC H1 HA mRNA vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A safety evaluation will occur to ensure the safety data support proceeding to the optimal dose group. N = 20
干预措施: Sodium Chloride, 0.9% (Other)
Arm 1
Healthy adults, 18 to 49 years of age will receive 10 mcg of DCVC H1 HA mRNA Vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A dose escalation safety evaluation will occur to ensure the safety data support proceeding to the higher dose group. N = 10
干预措施: DCVC H1 HA mRNA vaccine (Biological)
结局指标
主要结局
Number and percentage of participants experiencing any influenza like illnesses (ILI)
时间窗: Day 1 through Day 394
Number and percentage of participants experiencing any medically-attended adverse events (MAAEs)
时间窗: Day 1 through Day 394
Number and percentage of participants experiencing any serious adverse events (SAEs)
时间窗: Day 1 through Day 394
Number and percentage of participants with clinical laboratory adverse events (AEs)
时间窗: Day 1 through Day 57
Number and percentage of participants experiencing any unsolicited adverse events (AEs)
时间窗: Day 1 through Day 57
Number and percentage of participants experiencing any adverse events of special interest (AESIs)
时间窗: Day 1 through Day 394
Number and percentage of participants experiencing any new-onset chronic medical conditions (NOCMCs)
时间窗: Day 1 through Day 394
Number and percentage of participants experiencing solicited adverse events (AEs)
时间窗: Day 1 through Day 42
次要结局
- Geometric mean fold rise (GMFR) in homologous H1-specific anti-stalk serum antibodies(Day 1 through Day 57)
- Geometric mean fold rise (GMFR) in homologous H1-specific MN antibody(Day 1 through Day 57)
- Geometric mean fold rise in homologous H1-specific HAI antibody(Day 1 through 57)
- Geometric mean titers of homologous H1-specific anti-stalk serum antibodies(Day 1 through Day 57)
- Geometric mean titers of homologous H1-specific hemagglutinin inhibition (HAI) antibodies(Day 1 through Day 57)
- Geometric mean titers of homologous H1-specific microneutralization (MN) antibodies(Day 1 through Day 57)
- Number and percentage of participants achieving HAI titer seroconversion against the homologous H1-specific hemagglutinin(Day 1 through 57)
- Number and percentage of participants demonstrating HAI titer seroprotection against the homologous H1-specific hemagglutinin(Day 1 through 57)
- The number and percentage of participants achieving MN titer seroconversion against the homologous H1-specific hemagglutinin(Day 1 through 57)